ReversanSelective MRP1 and P-gp inhibitor CAS# 313397-13-6 |
2D Structure
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- Cephalexin hydrochloride
Catalog No.:BCC4095
CAS No.:59695-59-9
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
- Pefloxacin
Catalog No.:BCC4231
CAS No.:70458-92-3
- Pefloxacin Mesylate
Catalog No.:BCC4821
CAS No.:70458-95-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 313397-13-6 | SDF | Download SDF |
PubChem ID | 2298706 | Appearance | Powder |
Formula | C26H27N5O2 | M.Wt | 441.52 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 25 mM in DMSO | ||
Chemical Name | N-(3-morpholin-4-ylpropyl)-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide | ||
SMILES | C1COCCN1CCCNC(=O)C2=C3N=C(C=C(N3N=C2)C4=CC=CC=C4)C5=CC=CC=C5 | ||
Standard InChIKey | JTRXWCLQFAZHGP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C26H27N5O2/c32-26(27-12-7-13-30-14-16-33-17-15-30)22-19-28-31-24(21-10-5-2-6-11-21)18-23(29-25(22)31)20-8-3-1-4-9-20/h1-6,8-11,18-19H,7,12-17H2,(H,27,32) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp). Increases the sensitivity of MRP1-overexpressing tumor cells (MCF7/VP) to doxorubicin, vincristine and etoposide by 3.8-, 14.6- and 11.6-fold respectively. Increases the efficacy of vincristine and etoposide in murine models of neuroblastoma in vivo. Does not sensitize MRP2, MRP3, MRP4 or MRP5 transporters to known substrates. |
Reversan Dilution Calculator
Reversan Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2649 mL | 11.3245 mL | 22.649 mL | 45.2981 mL | 56.6226 mL |
5 mM | 0.453 mL | 2.2649 mL | 4.5298 mL | 9.0596 mL | 11.3245 mL |
10 mM | 0.2265 mL | 1.1325 mL | 2.2649 mL | 4.5298 mL | 5.6623 mL |
50 mM | 0.0453 mL | 0.2265 mL | 0.453 mL | 0.906 mL | 1.1325 mL |
100 mM | 0.0226 mL | 0.1132 mL | 0.2265 mL | 0.453 mL | 0.5662 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Regadenoson
Catalog No.:BCC6438
CAS No.:313348-27-5
- ICA 121431
Catalog No.:BCC6358
CAS No.:313254-51-2
- Aristolochic acid A
Catalog No.:BCN6262
CAS No.:313-67-7
- Estradiol Cypionate
Catalog No.:BCC4477
CAS No.:313-06-4
- Arjunic acid
Catalog No.:BCN5229
CAS No.:31298-06-3
- LDN-27219
Catalog No.:BCC6236
CAS No.:312946-37-5
- TCS JNK 5a
Catalog No.:BCC5148
CAS No.:312917-14-9
- Raucaffricine
Catalog No.:BCN4653
CAS No.:31282-07-2
- Hygromycin B
Catalog No.:BCC1204
CAS No.:31282-04-9
- Indacaterol
Catalog No.:BCC1650
CAS No.:312753-06-3
- gamma-Mangostin
Catalog No.:BCN5228
CAS No.:31271-07-5
- THIQ
Catalog No.:BCC7539
CAS No.:312637-48-2
- VU 590 dihydrochloride
Catalog No.:BCC7803
CAS No.:313505-85-0
- T0070907
Catalog No.:BCC2261
CAS No.:313516-66-4
- INH1
Catalog No.:BCC6040
CAS No.:313553-47-8
- Bombesin
Catalog No.:BCC5708
CAS No.:31362-50-2
- PD 118057
Catalog No.:BCC7499
CAS No.:313674-97-4
- 13-Oxo-9,11-octadecadienoic acid
Catalog No.:BCC8437
CAS No.:31385-09-8
- [Des-octanoyl]-Ghrelin (human)
Catalog No.:BCC7304
CAS No.:313951-59-6
- FLI-06
Catalog No.:BCC5110
CAS No.:313967-18-9
- o-3M3FBS
Catalog No.:BCC7210
CAS No.:313981-55-4
- PU 02
Catalog No.:BCC6265
CAS No.:313984-77-9
- [cPP1-7,NPY19-23,Ala31,Aib32,Gln34] - hPancreatic Polypeptide
Catalog No.:BCC5750
CAS No.:313988-89-5
- VDM 11
Catalog No.:BCC7044
CAS No.:313998-81-1
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.[Pubmed:19654298]
Cancer Res. 2009 Aug 15;69(16):6573-80.
The multidrug resistance-associated protein 1 (MRP1) has been closely linked to poor treatment response in several cancers, most notably neuroblastoma. Homozygous deletion of the MRP1 gene in primary murine neuroblastoma tumors resulted in increased sensitivity to MRP1 substrate drugs (vincristine, etoposide, and doxorubicin) compared with tumors containing both copies of wild-type MRP1, indicating that MRP1 plays a significant role in the drug resistance in this tumor type and defining this multidrug transporter as a target for pharmacologic suppression. A cell-based readout system was created to functionally determine intracellular accumulation of MRP1 substrates using a p53-responsive reporter as an indicator of drug-induced DNA damage. Screening of small-molecule libraries in this readout system revealed pyrazolopyrimidines as a prominent structural class of potent MRP1 inhibitors. Reversan, the lead compound of this class, increased the efficacy of both vincristine and etoposide in murine models of neuroblastoma (syngeneic and human xenografts). As opposed to the majority of inhibitors of multidrug transporters, Reversan was not toxic by itself nor did it increase the toxicity of chemotherapeutic drug exposure in mice. Therefore, Reversan represents a new class of nontoxic MRP1 inhibitor, which may be clinically useful for the treatment of neuroblastoma and other MRP1-overexpressing drug-refractory tumors by increasing their sensitivity to conventional chemotherapy.